Ignite Creation Date:
2024-05-06 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06116786
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-10-31
Brief Title:
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Sponsor:
Johnson Johnson Enterprise Innovation Inc
Organization:
Johnson Johnson Enterprise Innovation Inc
Study Overview
Official Title:
A Phase 1 Study of JNJ-86974680 an A2a Receptor Antagonist Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine a safe and tolerable doses of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-504818-29-00 | REGISTRY | None | None |
| 86974680NSC1001 | OTHER | Johnson Johnson Enterprise Innovation Inc | None |
| 2023-506393-12-00 | REGISTRY | None | None |